I believe that 2017 will turn out to be a break-out year for Exxon Mobil (NYSE:XOM) as a combination of higher oil pricing and an increase in low-cost production will help the company deliver strong revenue growth. More importantly, as Exxon ramps up its production from its low-cost assets, it will witness a rise in its bottom line performance over the long run. As a result, investors can expect....More>>>
Foreign central banks and government institutions sold $57.2 billion of U.S. Treasury debt and other notes in January, up from $48 billion in December, according a report on CNN Money. The report claims that this is the highest monthly tally on record going back to 1978.
It's part of a broader trend that gathered steam last year when central banks sold a record $225 billion of U.S.....More>>>
Ford (F) shares are higher Thursday, after its first quarter earnings beat expectations.
The automaker said it earned 68 cents a share, beating analysts average 47-cent estimate by a wide margin. However, revenue of $25.26 billion was just slightly below the consensus $35.84 billion.
The company reported a record pre-tax profit and operating margins in North....More>>>
An easy to understand enterprise that comes at an attractive valuation, Crown Crafts Inc (NASDAQ:CRWS) is cheap on free cashflows and the strength of its balance sheet. Having generated stable free cashflows in the last five years, I am highly convinced of company’s future free cash flow generation capabilities. If bought at the current market valuation of $ 76m,....More>>>
Chas Carey. (Photo courtesy of Chas Carey.)
Listen to the full episode here:
This week, Episode 32 of The Limit Does Not Exist, is a special C & C episode—but instead of Cate and Christina, it’s Cate and Chas! I sit down with Chas Carey, writer, producer, podcast host, litigator, actor… and Christina’s boyfriend.
That’s right! Just....More>>>
Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the....More>>>